Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852269 | 1.00 | TLR7 (0.85) | TLR7TLR8 | |
| SCHEMBL728467 | 0.95 | TLR7 (0.84) | TLR7TLR8 | |
| SCHEMBL3973102 | 0.94 | TLR7 (0.82) | TLR7TLR8 | |
| SCHEMBL3975772 | 0.94 | TLR7 (0.82) | TLR7TLR8 | |
| SCHEMBL3970575 | 0.93 | TLR7 (0.81) | TLR7TLR8 | |
| SCHEMBL3972423 | 0.92 | TLR7 (0.79) | TLR7TLR8 | |
| Cpg-52852 SCHEMBL483385 | 0.92 | TLR7 (1.00) | TLR7TLR8 | |
| Cpg-52852 SCHEMBL29371102 | 0.92 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL2743937 | 0.91 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL3970939 | 0.90 | TLR7 (0.70) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8961477-B2 | Delivery of immune response modifier compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-02-24 | — | — | US | claimed |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-08 | — | — | US | claimed |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-03 | — | — | US | claimed |
| US-20250312440-A1 | CHEMICAL SCREEN OF MODULATORS FOR VACCINE ADJUVANTS | THE UNIVERSITY OF CHICAGO (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250152703-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-15 | — | — | US | disclosed |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | THE UNIVERSITY OF CHICAGO | 2025-02-06 | — | — | US | disclosed |
| US-20250025542-A1 | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE TOLERANCE | THE UNIVERSITY OF CHICAGO (US) | 2025-01-23 | — | — | US | disclosed |
| US-12201684-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240417738-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION | 2024-12-19 | — | — | US | disclosed |
| CN-110234401-B | Methods and compositions for adaptive immunomodulation | 德克萨斯大学系统董事会 | 2024-03-01 | — | — | CN | disclosed |
| US-20240033348-A1 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Pulmotect, Inc. | 2024-02-01 | — | — | US | disclosed |
| US-20040265351-A1 | Methods and compositions for enhancing immune response | 3M INNOVATIVE PROPERTIES COMPANY | 2004-12-30 | — | — | US | disclosed |
| US-20040258698-A1 | Delivery of immune response modifier compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2004-12-23 | — | — | US | disclosed |
| WO-2004108072-A2 | DELIVERY OF IMMUNE RESPONSE MODIFIER COMPOUNDS USING METAL-CONTAINING PARTICULATE SUPPORT MATERIALS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040202720-A1 | Delivery of immune response modifier compounds using metal-containing particulate support materials | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-14 | — | — | US | disclosed |
| US-20040141950-A1 | Immunostimulatory combinations | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004060319-A2 | IMMUNOSTIMULATORY COMBINATIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-08 | — | — | US | disclosed |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-03 | — | — | US | disclosed |
| US-6677349-B1 | INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040265351-A1 | Methods and compositions for enhancing immune response | LRBA, CD69, MYD88 | TLR7 59/4885TLR8 60/4885 |
| US-20040258698-A1 | Delivery of immune response modifier compounds | MIF, IRF3, CLEC4M | TLR7 126/4885TLR8 51/4885 |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885TLR8 71/4885 |
| US-20250041408-A1 | SMALL MOLECULE IMMUNOPOTENTIATOR CONJUGATES OF NFKB ACTIVATORS AS ADJUVANTS WITH ENHANCED EFFICACY AND REDUCED TOXICITY | NFKBIA, NFRKB, NFKB2 | TLR7 20/4885TLR8 9/4885 |
| US-20040202720-A1 | Delivery of immune response modifier compounds using metal-containing particulate support materials | MIF, IRF3, IRF2BP2 | TLR7 131/4885TLR8 99/4885 |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885TLR8 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.